Clinical Trials Logo
  1. Home
  2. SCLC
  3. NCT01797874
  4. Details
NCT01797874 Clinical Trial

Pazopanib Maintenance for SCLC

SCLC Clinical Trial

Official title:
Phase II Study of Pazopanib Maintenance for SCLC

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01797874
Other study ID # 2012-09-060-002
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2013
Est. completion date December 2017

Study information
Verified date December 2019
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Recruitment information / eligibility
Status Completed
Enrollment 97
Est. completion date December 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- histologically confirmed SCLC

- no disease progression after 4 cycles of etoposide/platinum 1st-line therapy

- history of 4 cycles of etoposide/platinum 1st-line therapy

- between 21 days and 42 days since C4D1 of etoposide/platinum

- no symptomatic brain meta

Exclusion Criteria:

- poor hepatic, renal function

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Pazopanib
Experimental
• Placebo
placebo arm

Locations
Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)
Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Progression-free survival 12 months
See also
  Status Clinical Trial Phase
Completed NCT05026593 - A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT00046787 - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer Phase 2
Recruiting NCT04826341 - A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Phase 1/Phase 2
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Withdrawn NCT04677361 - Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab Early Phase 1
Terminated NCT00522639 - Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation Phase 3
Completed NCT03428607 - Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] Phase 2
Recruiting NCT05546268 - Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Not yet recruiting NCT03244904 - Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment N/A
Completed NCT01713296 - Pazopanib in Relapsed and Refractory Small Cell Lung Cancer Phase 2
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Recruiting NCT05130255 - GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 Phase 1
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Recruiting NCT05879068 - A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC Phase 2
Recruiting NCT04684017 - Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer Phase 2
Completed NCT00346385 - BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1